Editas Medicine (EDIT) Operating Income (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Operating Income of -$24.5 million for Q3 2025, up 62.62% year-over-year from -$15.1 million in Q3 2024, and up 52.37% quarter-over-quarter from -$51.5 million in Q2 2025.
Editas Medicine (EDIT) Operating Income (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Operating Income for 11 consecutive years, with -$24.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Operating Income rose 62.62% year-over-year to -$24.5 million; the TTM figure through Sep 2025 stood at -$198.8 million (up 12.99% YoY), while the FY2024 annual figure was -$251.2 million, down 48.45% from the prior year.
- Operating Income rose to -$24.5 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$24.0 million in Q4 2023 and bottomed at -$76.2 million in Q1 2025.
- Historically, Operating Income has averaged -$52.2 million across 5 years, with a median of -$51.5 million in 2025.
- Annual changes were most pronounced in 2021 — Operating Income slumped 536.68% — and 2025, when it soared 62.62%.
- Editas Medicine's Operating Income stood at -$41.6 million in 2021, then tumbled by 52.48% to -$63.4 million in 2022, then surged by 62.23% to -$24.0 million in 2023, then sank by 94.45% to -$46.6 million in 2024, then surged by 47.31% to -$24.5 million in 2025.
- Business Quant data shows EDIT's Operating Income at -$24.5 million in Q3 2025, -$51.5 million in Q2 2025, and -$76.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.55 Mn |
| Jun 30, 2025 | -51.54 Mn |
| Mar 31, 2025 | -76.16 Mn |
| Dec 31, 2024 | -46.59 Mn |
| Sep 30, 2024 | -65.67 Mn |
| Jun 30, 2024 | -71.90 Mn |
| Mar 31, 2024 | -66.99 Mn |
| Dec 31, 2023 | -23.96 Mn |
| Sep 30, 2023 | -50.16 Mn |
| Jun 30, 2023 | -44.09 Mn |
| Mar 31, 2023 | -50.96 Mn |
| Dec 31, 2022 | -63.45 Mn |
| Sep 30, 2022 | -57.52 Mn |
| Jun 30, 2022 | -54.23 Mn |
| Mar 31, 2022 | -50.75 Mn |
| Dec 31, 2021 | -41.61 Mn |
| Sep 30, 2021 | -39.25 Mn |
| Jun 30, 2021 | -55.40 Mn |
| Mar 31, 2021 | -56.88 Mn |
| Dec 31, 2020 | -65.87 Mn |